AC Immune SA (NASDAQ: ACIU) can be an appealing option for investors seeking high-upside exposure to clinical-stage biotechnology innovation, particularly those focused on targeted treatments for neurodegenerative diseases. Analysts tracking the firm emphasize its robust intellectual property portfolio, proprietary technology platforms, and lucrative co-development partnerships with global pharmaceutical leaders as strong positive catalysts. Nevertheless, because clinical trial outcomes are unpredictable and regulatory hurdles can impact timelines, the stock remains a high-risk, speculative asset suited primarily for investors comfortable with biotechnology sector volatility.